Laboratory evaluations in HIV-1-associated cognitive/motor complex

Area of Science:

• Neuroscience
• Infectious Diseases
• Medical Diagnostics

Background:

• Human Immunodeficiency Virus type 1 (HIV-1) can affect the central nervous system (CNS).
• HIV-1-associated cognitive and motor complex is a clinical diagnosis, often made after other neurological conditions are excluded.
• Current laboratory tests lack definitive diagnostic or prognostic markers for HIV-1 CNS disease.

Purpose of the Study:

• To review the utility of laboratory tests in diagnosing and monitoring HIV-1 CNS effects.
• To identify promising biomarkers for early detection and treatment evaluation of HIV-1 neurological complications.

Main Methods:

• Review of current and emerging laboratory diagnostic procedures for HIV-1 CNS disease.
• Analysis of Magnetic Resonance (MR) imaging, cerebrospinal fluid (CSF) examinations, and advanced neuroimaging techniques.
• Evaluation of electrophysiologic methods and specific CSF biomarkers.

Main Results:

• MR imaging and CT scans lack sensitivity for early HIV-1 CNS detection or monitoring disease progression.
• Certain CSF variables, including quinolinic acid, p24 antigen, neopterin, beta 2m, and intrathecal IgG synthesis, show potential as early markers.
• Advanced research tools like PET, SPECT, and electrophysiologic methods show promise but require further validation.

Conclusions:

• HIV-1-associated cognitive/motor complex remains a clinical diagnosis.
• CSF markers and electrophysiologic methods are valuable adjuncts, providing presumptive evidence of CNS damage.
• Longitudinal studies are needed to validate new diagnostic and prognostic markers for HIV-1 neurological disease.